BioSpace News Archive

BioMidwest

TherapeuticsMD Secures $15 Million Equity Investment from Rubric Capital

TherapeuticsMD, Inc., an innovative, leading women’s healthcare company, announced that it has received a $15 million private investment in the Company’s common stock and a new series of preferred stock from Rubric Capital Management LP.

August 1, 2022
·
6 min read
Business

atai Life Sciences to Announce Second Quarter 2022 Financial Results and Business Update

atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, plans to announce its second quarter 2022 financial results and business update on Monday, August 15, 2022.

August 1, 2022
·
1 min read
Business

BioXcel Therapeutics Announces NIH NIDA Grant to Columbia University to Support Further Studies of BXCL501 (Sublingual Dexmedetomidine) for Treating Opioid Withdrawal

BioXcel Therapeutics, Inc. today announced that the National Institute on Drug Abuse, part of the National Institutes of Health (NIH), has awarded Columbia University a multi-year NIDA grant to fund clinical testing of BXCL501 (sublingual dexmedetomidine) as a potential treatment for opioid withdrawal.

August 1, 2022
·
7 min read
Pharm Country

Tonix Pharmaceuticals Announces Issuance of U.S. Patent Covering Potentiated Intranasal Oxytocin (TNX-1900) for the Treatment of Pain

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that the United States Patent and Trademark Office (USPTO) issued U.S. Patent 11,389,473 to the Company on July 19, 2022.

August 1, 2022
·
9 min read
Business

Chemomab Therapeutics to Report Second Quarter 2022 Financial Results and Provide a Business Update

Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), today announced the company will release its second quarter 2022 financial results and provide a business update on Friday, August 12, 2022 at 8:00 am Eastern Time.

August 1, 2022
·
2 min read
Genetown

AVROBIO to Participate in Two Upcoming Investor Conferences in August

AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in two upcoming investor conferences.

August 1, 2022
·
5 min read
Genetown

Gamida Cell Announces FDA Acceptance of Biologics License Application for Omidubicel with Priority Review

Gamida Cell Ltd. announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s Biologics License Application (BLA) for omidubicel for the treatment of patients with blood cancers in need of an allogenic hematopoietic stem cell transplant.

August 1, 2022
·
8 min read
Deals

Catalyst Biosciences Announces Support from Largest Single Stockholder

JEC Capital Partners Agrees to Vote Its Shares in Favor of Catalyst’s Nominees at the Company’s 2022 Annual Meeting Michael Torok from JEC Appointed as an Observer to the Transaction Committee of the Board of Directors.

August 1, 2022
·
6 min read
Deals

Navidea Biopharmaceuticals Reminds Investors of Today’s Deadline to be a Shareholder of Record for the Previously Announced Rights Offering

Navidea Biopharmaceuticals, Inc. today issued a reminder to shareholders that the record date of its proposed rights offering is Wednesday, August 3, 2022 (“Record Date”).

August 1, 2022
·
6 min read
Eitan Medical Receives ISO 14001 Environmental Management Certification

Eitan Medical announced today it has earned International Organization for Standardization (ISO) 14001 certification for the quality management system for production of its range of medical devices including its Sapphire infusion pumps and the Sorrel™ wearable drug delivery platform solution.

August 1, 2022
·
3 min read